Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8933 |
High Similarity |
NPD4965 |
Approved |
0.8933 |
High Similarity |
NPD4967 |
Phase 2 |
0.8933 |
High Similarity |
NPD4966 |
Approved |
0.8733 |
High Similarity |
NPD37 |
Approved |
0.8693 |
High Similarity |
NPD6234 |
Discontinued |
0.8428 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8344 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8298 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8221 |
Intermediate Similarity |
NPD7240 |
Approved |
0.8125 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8116 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7961 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7922 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7871 |
Intermediate Similarity |
NPD1653 |
Approved |
0.78 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7755 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7755 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7647 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7643 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7622 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7622 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7591 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7582 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7556 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7552 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7534 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7528 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7456 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7423 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7419 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7419 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7399 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7396 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7383 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7362 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7362 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7353 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7326 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7294 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7285 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7267 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7267 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7261 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7239 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7237 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7226 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7226 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7225 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7215 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7209 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7202 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7195 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7188 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7186 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7181 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7176 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7171 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7171 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7171 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7168 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.716 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7134 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7124 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7118 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7118 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7118 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7117 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7115 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7108 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7095 |
Intermediate Similarity |
NPD7296 |
Approved |
0.7091 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7091 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7089 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7086 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7078 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7075 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7063 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7051 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7044 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7039 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7029 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7027 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7022 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7022 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7022 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7019 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7014 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7013 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7011 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7006 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7006 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD3686 |
Approved |
0.6994 |
Remote Similarity |
NPD3687 |
Approved |
0.6993 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD7157 |
Approved |
0.6988 |
Remote Similarity |
NPD7819 |
Suspended |
0.6988 |
Remote Similarity |
NPD2801 |
Approved |
0.6988 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6986 |
Remote Similarity |
NPD5126 |
Approved |
0.6986 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6975 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6966 |
Remote Similarity |
NPD1548 |
Phase 1 |
0.6962 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD5242 |
Approved |
0.695 |
Remote Similarity |
NPD228 |
Approved |
0.6946 |
Remote Similarity |
NPD5353 |
Approved |
0.6943 |
Remote Similarity |
NPD3539 |
Phase 1 |
0.6937 |
Remote Similarity |
NPD2219 |
Phase 1 |
0.6937 |
Remote Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD3384 |
Approved |
0.6928 |
Remote Similarity |
NPD3382 |
Approved |
0.6928 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6928 |
Remote Similarity |
NPD3383 |
Approved |
0.6923 |
Remote Similarity |
NPD6111 |
Discontinued |
0.6918 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD5585 |
Approved |
0.6914 |
Remote Similarity |
NPD2533 |
Approved |
0.6914 |
Remote Similarity |
NPD2532 |
Approved |
0.6914 |
Remote Similarity |
NPD2534 |
Approved |
0.6909 |
Remote Similarity |
NPD4678 |
Approved |
0.6909 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6909 |
Remote Similarity |
NPD4675 |
Approved |
0.6903 |
Remote Similarity |
NPD5735 |
Approved |
0.6901 |
Remote Similarity |
NPD5535 |
Approved |
0.6901 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6901 |
Remote Similarity |
NPD7843 |
Approved |
0.6897 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD4210 |
Discontinued |
0.6886 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD4108 |
Discontinued |
0.6879 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6879 |
Remote Similarity |
NPD5588 |
Approved |
0.6875 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6871 |
Remote Similarity |
NPD17 |
Approved |
0.6867 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD1283 |
Approved |
0.6864 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6863 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6857 |
Remote Similarity |
NPD2684 |
Approved |
0.6852 |
Remote Similarity |
NPD6799 |
Approved |
0.6845 |
Remote Similarity |
NPD5006 |
Approved |
0.6845 |
Remote Similarity |
NPD5005 |
Approved |
0.6845 |
Remote Similarity |
NPD5402 |
Approved |
0.6839 |
Remote Similarity |
NPD2979 |
Phase 3 |
0.6839 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD6032 |
Approved |
0.6826 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6824 |
Remote Similarity |
NPD919 |
Approved |
0.6824 |
Remote Similarity |
NPD3847 |
Discontinued |
0.6815 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD4536 |
Approved |
0.6815 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD4538 |
Approved |
0.6813 |
Remote Similarity |
NPD3060 |
Approved |
0.6813 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6809 |
Remote Similarity |
NPD3021 |
Approved |
0.6809 |
Remote Similarity |
NPD3022 |
Approved |
0.6807 |
Remote Similarity |
NPD6599 |
Discontinued |
0.6803 |
Remote Similarity |
NPD5691 |
Approved |
0.6795 |
Remote Similarity |
NPD3657 |
Discovery |
0.679 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6788 |
Remote Similarity |
NPD7827 |
Phase 1 |
0.6786 |
Remote Similarity |
NPD1358 |
Approved |
0.6774 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.677 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.677 |
Remote Similarity |
NPD3750 |
Approved |
0.6763 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6757 |
Remote Similarity |
NPD4626 |
Approved |
0.675 |
Remote Similarity |
NPD5958 |
Discontinued |
0.6748 |
Remote Similarity |
NPD1511 |
Approved |
0.674
|
Remote Similarity |
NPD7243 |
Clinical (unspecified phase) |